Skip to main content
Jiangsu Jibeier Pharmaceutical Co.,Ltd. logo

Jiangsu Jibeier Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 688566 ISIN · CNE100004041 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 605 across all filing types
Latest filing 2026-05-22 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688566

About Jiangsu Jibeier Pharmaceutical Co.,Ltd.

https://www.jbepharm.com/

Jiangsu Jibeier Pharmaceutical Co., Ltd. is a high-tech enterprise focused on the research, development, production, and sales of innovative chemical drugs and biological products. The company specializes in several therapeutic areas, including ophthalmology, cardiovascular diseases, and oncology. Its product portfolio features specialized treatments such as sodium hyaluronate eye drops and various formulations designed for chronic disease management. Jibeier emphasizes technological innovation, maintaining advanced R&D platforms for drug delivery systems and high-end formulations. The company operates modern production facilities compliant with rigorous quality standards, aiming to provide effective therapeutic solutions for clinical needs. Its strategic focus remains on the development of proprietary intellectual property and the commercialization of specialized pharmaceutical agents.

Recent filings

Filing Released Lang Actions
吉贝尔关于召开2025年度暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 80% confidence The document is an announcement by Jiangsu Jibeier Pharmaceutical Co., Ltd. convening a 2025 annual and 2026 first-quarter performance explanation meeting (业绩说明会) to interact with investors. It provides meeting time, platform, participants, and Q&A details. It is not the actual financial report (those have already been published) nor a mere report publication notice—it is arranging an investor presentation. This best fits the “Investor Presentation” category.
2026-05-22 Chinese
吉贝尔2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 88% confidence The document is the official announcement of the 2025 Annual General Meeting’s resolutions, detailing attendance, proposals considered, and precise voting results for each agenda item. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-22 Chinese
北京市金杜（南京）律师事务所关于江苏吉贝尔药业股份有限公司2025年限制性股票激励计划首次授予部分第一个归属期归属条件成就及部分限制性股票作废相关事项之法律意见书
Regulatory Filings Classification · 85% confidence The document is a standalone legal opinion letter issued by a law firm (King & Wood) concerning the 2025 restricted stock incentive plan of Jiangsu Gebel Pharmaceutical Co., specifically addressing vesting achievements and stock cancellations. It is not a financial report, earnings release, board appointment notice, capital transaction, or other specific category. It forms part of the regulatory/compliance disclosures rather than constituting the report itself. Therefore, it should be classified under the fallback category “Regulatory Filings” (RNS).
2026-05-20 Chinese
吉贝尔关于2025年限制性股票激励计划首次授予部分第一个归属期归属条件成就的公告
Share Issue/Capital Change Classification · 85% confidence The document is a formal corporate announcement detailing the achievement of vesting conditions and the planned issuance of 1,670,760 restricted shares under the company’s 2025 stock incentive plan. It is not a financial report, proxy statement, or regulatory certification but rather a share‐based compensation issuance. Under the taxonomy, such announcements of new share issues and related capital changes fall under Share Issue/Capital Change (SHA).
2026-05-20 Chinese
吉贝尔薪酬与考核委员会关于2025年限制性股票激励计划首次授予部分第一个归属期归属名单的核查意见
Remuneration Information Classification · 65% confidence The document is a Compensation and Assessment Committee opinion on the first vesting list of a 2025 restricted stock incentive plan, detailing approval of share grants to management and staff under the company’s equity incentive plan. This falls under remuneration and equity incentive disclosures by governance bodies, matching the “Remuneration Information” category.
2026-05-20 Chinese
吉贝尔第四届董事会第二十二次会议决议公告
Regulatory Filings Classification · 75% confidence The document is a formal announcement of the board of directors’ meeting resolutions (approving equity incentive plan vesting, cancelling unvested restricted shares, voting results, etc.). It does not contain financial statements (so it is not an Interim or Annual Report), nor does it announce changes in management personnel (so it is not a MANG filing). It merely sets out board resolutions and votes, which is a general regulatory announcement. Therefore, the correct category is a general Regulatory Filing (RNS).
2026-05-20 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.